CoreWeave is becoming integral to AI infrastructure build-out. CoreWeave's growth is a compelling reason to buy the stock, but there is one glaring red flag that investors can't afford to miss. Are ...

United States stock markets will be closed on Thursday, Nov. 27, and will close early on Friday, Nov. 28, in observance of the Thanksgiving holiday and Black Friday. After closing for the Thanksgiving ...

While advertising revenue is firmly in the driver's seat for growth, accounting for 94% of revenue in Q3, Reddit does have some opportunities from AI data licensing ...

Galaxy Digital is fundamentally undervalued, trading at $25 despite a fair value estimate of $50-$70 per share for its data center infrastructure business. Galaxy acquired Helios for $65M in 2022, ...

A day after Thursday’s anxiety-inducing fake out, Friday turned into Redemption Day on Wall Street. The Dow ended the day 493 points higher, or 1.08%, after gaining as much as 800 points earlier in ...

The U.S. stock market sank sharply in early trading, with investors increasingly skittish about the strength of the artificial intelligence boom. The S&P 500, which set a record high in late October, ...

The Nasdaq Composite locked in its best day since May after a group of Senate Democrats joined Republicans to advance a bill to end the government shutdown. The Nasdaq rose 2.3% to mark its largest ...

Big stock gains have always been followed by big losses. Here are tips on how to prepare. By Jeff Sommer Jeff Sommer writes Strategies, a weekly column on markets, finance and the economy. The higher ...

The stock market fell again on Thursday as Wall Street continued to sell riskier technology and consumer discretionary stocks in the wake of some weaker labor market data. The Dow Jones Industrial ...

The amount of capital pouring into AI data center projects is staggering. Last week, Microsoft, Alphabet, Meta, and Amazon reported their 2025 capital expenditures would total roughly $370 billion, ...

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Biohaven's New Drug Application (NDA) seeking approval of Vyglxia (troriluzole) for spinocerebellar ataxia (SCA).

The stock market has spent most of 2025 defying both gravity and logic. Despite persistent geopolitical tensions in Europe and the Middle East, new tariffs, and unease over the timing of the Federal ...